The challenge of the microenvironment in B-cell lymphomas

Histopathology

Volumn 58, Issue 1, 2011, Pages 69-80

  Coupland, Sarah E ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

B cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Marginal zone B cell lymphoma; Microenvironment

Indexed keywords

CD20 ANTIGEN; CD3 ANTIGEN; CD30 LIGAND; CD31 ANTIGEN; CD4 ANTIGEN; CD40 LIGAND; CD5 ANTIGEN; CD68 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CXCL13 CHEMOKINE; CYCLIN D1; IMMUNOGLOBULIN; IMMUNOGLOBULIN M; INTERLEUKIN 15; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; JAGGED1; KI 67 ANTIGEN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; SECONDARY LYMPHOID TISSUE CHEMOKINE; SOMATOMEDIN BINDING PROTEIN 1; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR; UNINDEXED DRUG; VASCULOTROPIN; VON WILLEBRAND FACTOR;

ANGIOGENESIS; B CELL LYMPHOMA; B LYMPHOCYTE; CANCER CELL; CANCER GROWTH; CELL GROWTH; CELL MATURATION; CELL MIGRATION; CELL POPULATION; CLASSICAL HODGKIN LYMPHOMA; FOLLICULAR DENDRITIC CELL; FOLLICULAR LYMPHOMA; HEDGEHOG; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LYMPH NODE; LYMPHOID ORGAN; LYMPHOID TISSUE; MACROPHAGE; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MICROENVIRONMENT; NONHODGKIN LYMPHOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RETICULUM CELL; REVIEW; SPLEEN; STROMA CELL; T LYMPHOCYTE; TH17 CELL;

ANIMALS; CELL DIFFERENTIATION; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, B-CELL; LYMPHOMA, FOLLICULAR; LYMPHOMA, T-CELL; STROMAL CELLS; T-LYMPHOCYTES, REGULATORY; TUMOR MICROENVIRONMENT;

EID: 78851470309     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2010.03706.x     Document Type: Review

References (90)

1. Harris NL, Stein H, Coupland SE et al. New approaches to lymphoma diagnosis. Hematology (Am. Soc. Hematol. Educ. Program) 2001; 194-220.
2. Dave SS, Wright G, Tan B et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N. Engl. J. Med. 2004; 351; 2159-2169.
3. Lenz G, Wright G, Dave SS et al. Stromal gene signatures in large-B-cell lymphomas. N. Engl. J. Med. 2008; 359; 2313-2323.
4. Swerdlow SH, Campo E, Harris NL et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC, 2008.
5. Jaffe ES, Harris NL, Stein H, Isaacson PG. Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood 2008; 112; 4384-4399.
6. Isaacson PG, Du MQ. MALT lymphoma: from morphology to molecules. Nat. Rev. Cancer 2004; 4; 644-653.
7. Miyasaka M, Tanaka T. Lymphocyte trafficking across high endothelial venules: dogmas and enigmas. Nat. Rev. Immunol. 2004; 4; 360-370.
8. Bajenoff M, Egen JG, Koo LY et al. Stromal cell networks regulate lymphocyte entry, migration, and territoriality in lymph nodes. Immunity 2006; 25; 989-1001.
9. Cyster JG, Ansel KM, Reif K et al. Follicular stromal cells and lymphocyte homing to follicles. Immunol. Rev. 2000; 176; 181-193.
10. Nakano H, Mori S, Yonekawa H, Nariuchi H, Matsuzawa A, Kakiuchi T. A novel mutant gene involved in T-lymphocyte-specific homing into peripheral lymphoid organs on mouse chromosome 4. Blood 1998; 91; 2886-2895.
11. Forster R, Schubel A, Breitfeld D et al. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 1999; 99; 23-33.
12. Ansel KM, Ngo VN, Hyman PL et al. A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature 2000; 406; 309-314.
13. Bajenoff M, Glaichenhaus N, Germain RN. Fibroblastic reticular cells guide T lymphocyte entry into and migration within the splenic T cell zone. J. Immunol. 2008; 181; 3947-3954.
14. Bajenoff M, Germain RN. B-cell follicle development remodels the conduit system and allows soluble antigen delivery to follicular dendritic cells. Blood 2009; 114; 4989-4997.
15. Katakai T, Hara T, Lee JH, Gonda H, Sugai M, Shimizu A. A novel reticular stromal structure in lymph node cortex: an immuno-platform for interactions among dendritic cells, T cells and B cells. Int. Immunol. 2004; 16; 1133-1142.
16. Kim MY, McConnell FM, Gaspal FM et al. Function of CD4+CD3- cells in relation to B- and T-zone stroma in spleen. Blood 2007; 109; 1602-1610.
17. Ngo VN, Cornall RJ, Cyster JG. Splenic T zone development is B cell dependent. J. Exp. Med. 2001; 194; 1649-1660.
18. Murakami T, Chen X, Hase K, Sakamoto A, Nishigaki C, Ohno H. Splenic CD19-CD35+B220+ cells function as an inducer of follicular dendritic cell network formation. Blood 2007; 110; 1215-1224.
19. Katakai T, Hara T, Sugai M, Gonda H, Shimizu A. Lymph node fibroblastic reticular cells construct the stromal reticulum via contact with lymphocytes. J. Exp. Med. 2004; 200; 783-795.
20. Gascoyne RD, Rosenwald A, Poppema S, Lenz G. Prognostic biomarkers in malignant lymphomas. Leuk. Lymphoma 2010; S1(Suppl. 1): 11-19.
21. Jundt F, Anagnostopoulos I, Forster R, Mathas S, Stein H, Dorken B. Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood 2002; 99; 3398-3403.
22. Jundt F, Pröbsting KS, Anagnostopoulos I et al. Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells. Blood 2004; 103; 3511-3515.
23. Aldinucci D, Gloghini A, Pinto A, De Filippi R, Carbone A. The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. J. Pathol. 2010; 221; 248-263.
24. Calvo KR, Dabir B, Kovach A et al. IL-4 protein expression and basal activation of Erk invivo in follicular lymphoma. Blood 2008; 112; 3818-3826.
25. Dierks C, Grbic J, Zirlik K et al. Essential role of stromally induced hedgehog signaling in B-cell malignancies. Nat. Med. 2007; 13; 944-951.
26. Lindemann RK. Stroma-initiated hedgehog signaling takes center stage in B-cell lymphoma. Cancer Res. 2008; 68; 961-964.
27. Singh RR, Kim JE, Davuluri Y et al. Hedgehog signaling pathway is activated in diffuse large B-cell lymphoma and contributes to tumor cell survival and proliferation. Leukemia 2010; 24; 1025-1036.
28. Farinha P, Masoudi H, Skinnider BF et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL), Blood 2005; 106; 2169-2174.
29. Alvaro T, Lejeune M, Salvadó MT et al. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J. Clin. Oncol. 2006; 24; 5350-5357.
30. Canioni D, Salles G, Mounier N et al. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J. Clin. Oncol. 2008; 26; 440-446.
31. Taskinen M, Karjalainen-Lindsberg ML, Nyman H, Eerola LM, Leppa S. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. Clin. Cancer Res. 2007; 13; 5784-5789.
32. Lejeune M, Alvaro T. Clinicobiological, prognostic and therapeutic implications of the tumor microenvironment in follicular lymphoma. Haematologica 2009; 94; 16-21.
33. Byers RJ, Sakhinia E, Joseph P et al. Clinical quantitation of immune signature in follicular lymphoma by RT-PCR-based gene expression profiling. Blood 2008; 111; 4764-4770.
34. Harjunpää A, Taskinen M, Nykter M et al. Differential gene expression in non-malignant tumour microenvironment is associated with outcome in follicular lymphoma patients treated with rituximab and CHOP. Br. J. Haematol. 2006; 135; 33-42.
35. Zelenetz AD, Campbell MJ, Bahler DW et al. Follicular lymphoma: a model of lymphoid tumor progression in man. Ann. Oncol. 1991; 2(Suppl. 2); 115-122.
36. Zelenetz AD, Chen TT, Levy R. Clonal expansion in follicular lymphoma occurs subsequent to antigenic selection. J. Exp. Med. 1992; 176; 1137-1148.
37. Carreras J, Lopez-Guillermo A, Fox BC et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 2006; 108; 2957-2964.
38. Lee AM, Clear AJ, Calaminici M et al. Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J. Clin. Oncol. 2006; 24; 5052-5059.
39. Glas AM, Knoops L, Delahaye L et al. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J. Clin. Oncol. 2007; 25; 390-398.
40. Wahlin BE, Sander B, Christensson B, Kimby E. CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma. Clin. Cancer Res. 2007; 13; 388-397.
41. Carreras J, Lopez-Guillermo A, Roncador G et al. High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma. J. Clin. Oncol. 2009; 27; 1470-1476.
42. Manconi R, Poletti A, Volpe R, Sulfaro S, Carbone A. Dendritic reticulum cell pattern as a microenvironmental indicator for a distinct origin of lymphoma of follicular mantle cells. Br. J. Haematol. 1988; 68; 213-218.
43. Carbone A, Gloghini A, Gruss HJ, Pinto A. CD40 ligand is constitutively expressed in a subset of T cell lymphomas and on the microenvironmental reactive T cells of follicular lymphomas and Hodgkin's disease. Am. J. Pathol. 1995; 147; 912-922.
44. Liu YJ, Malisan F, de Bouteiller O et al. Within germinal centers, isotype switching of immunoglobulin genes occurs after the onset of somatic mutation. Immunity 1996; 4; 241-250.
45. Klein U, Goosens T, Fischer M et al. Somatic hypermutation in normal and transformed human B cells. Immunol. Rev. 1998; 162; 261-280.
46. Manz RA, Hauser AE, Hiepe F, Radbruch A. Maintenance of serum antibody levels. Annu. Rev. Immunol. 2005; 23; 367-386.
47. Dorfman DM, Schultze JL, Shahsafaei A et al. Invivo expression of B7-1 and B7-2 by follicular lymphoma cells can prevent induction of T-cell anergy but is insufficient to induce significant T-cell proliferation. Blood 1997; 90; 4297-4306.
48. Vyth-Dreese FA, Boot H, Dellemijn TA et al. Localization insitu of costimulatory molecules and cytokines in B-cell non-Hodgkin's lymphoma. Immunology 1998; 94; 580-586.
49. Koopman G, Keehnen RM, Lindhout E et al. Adhesion through the LFA-1 (CD11a/CD18)-ICAM-1 (CD54) and the VLA-4 (CD49d)-VCAM-1 (CD106) pathways prevents apoptosis of germinal center B cells. J. Immunol. 1994; 152; 3760-3767.
50. Park CS, Choi YS. How do follicular dendritic cells interact intimately with B cells in the germinal centre? Immunology 2005; 114; 2-10.
51. Li L, Zhang X, Kovacic S et al. Identification of a human follicular dendritic cell molecule that stimulates germinal center B cell growth. J. Exp. Med. 2000; 191; 1077-1084.
52. Hase H, Kanno Y, Kojima M et al. BAFF/BLyS can potentiate B-cell selection with the B-cell coreceptor complex. Blood 2004; 103; 2257-2265.
53. Zhang X, Park CS, Yoon SO et al. BAFF supports human B cell differentiation in the lymphoid follicles through distinct receptors. Int. Immunol. 2005; 17; 779-788.
54. van der Voort R, Taher TE, Keehnen RM, Smit L, Groenink M, Pals ST. Paracrine regulation of germinal center B cell adhesion through the c-met-hepatocyte growth factor/scatter factor pathway. J. Exp. Med. 1997; 185; 2121-2131.
55. Tjin EP, Bende RJ, Derksen PW et al. Follicular dendritic cells catalyze hepatocyte growth factor (HGF) activation in the germinal center microenvironment by secreting the serine protease HGF activator. J. Immunol. 2005; 175; 2807-2813.
56. Endres R, Alimzhanov MB, Plitz T et al. Mature follicular dendritic cell networks depend on expression of lymphotoxin beta receptor by radioresistant stromal cells and of lymphotoxin beta and tumor necrosis factor by B cells. J. Exp. Med. 1999; 189; 159-168.
57. Matsumoto M, Fu YX, Molina H et al. Distinct roles of lymphotoxin alpha and the type I tumor necrosis factor (TNF) receptor in the establishment of follicular dendritic cells from non-bone marrow-derived cells. J. Exp. Med. 1997; 186; 1997-2004.
58. Victoratos P, Lagnel J, Tzima S et al. FDC-specific functions of p55TNFR and IKK2 in the development of FDC networks and of antibody responses. Immunity 2006; 24; 65-77.
59. Mackay F, Browning JL. Turning off follicular dendritic cells. Nature 1998; 395; 26-27.
60. Gommerman JL, Mackay F, Donskoy E, Meier W, Martin P, Browning JL. Manipulation of lymphoid microenvironments in nonhuman primates by an inhibitor of the lymphotoxin pathway. J. Clin. Invest. 2002; 110; 1359-1369.
61. Voog E, Bienvenu J, Warzocha K et al. Factors that predict chemotherapy-induced myelosuppression in lymphoma patients: role of the tumor necrosis factor ligand-receptor system. J. Clin. Oncol. 2000; 18; 325-331.
62. Travert M, Ame-Thomas P, Pangault C et al. CD40 ligand protects from TRAIL-induced apoptosis in follicular lymphomas through NF-kappaB activation and up-regulation of c-FLIP and Bcl-xL. J. Immunol. 2008; 181; 1001-1011.
63. Johnson PW, Watt SM, Betts DR et al. Isolated follicular lymphoma cells are resistant to apoptosis and can be grown invitro in the CD40/stromal cell system. Blood 1993; 82; 1848-1857.
64. Umetsu DT, Esserman L, Donlon TA, DeKruyff RH, Levy R. Induction of proliferation of human follicular (B type) lymphoma cells by cognate interaction with CD4+ T cell clones. J. Immunol. 1990; 144; 2550-2557.
65. Eeva J, Postila V, Matto M et al. Kinetics and signaling requirements of CD40-mediated protection from B cell receptor-induced apoptosis. Eur. J. Immunol. 2003; 33; 2783-2791.
66. Homig-Holzel C, Hojer C, Rastelli J et al. Constitutive CD40 signaling in B cells selectively activates the noncanonical NF-kappaB pathway and promotes lymphomagenesis. J. Exp. Med. 2008; 205; 1317-1329.
67. Fanale MA, Younes A. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. Drugs 2007; 67; 333-350.
68. Horna P, Cuenca A, Cheng F et al. Invivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunity. Blood 2006; 107; 2871-2878.
69. Plumas J, Jacob MC, Chaperot L, Molens JP, Sotto JJ, Bensa JC. Tumor B cells from non-Hodgkin's lymphoma are resistant to CD95 (Fas/Apo-1)-mediated apoptosis. Blood 1998; 91; 2875-2885.
70. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299; 1057-1061.
71. Wei WZ, Morris GP, Kong YC. Antitumor immunity and autoimmunity: a balancing act of regulatory T cells. Cancer Immunol. Immunother. 2004; 53; 73-78.
72. Beyer M, Schultze JL. Regulatory T cells in cancer. Blood 2006; 108; 804-811.
73. Curiel TJ, Cheng P, Mottram P et al. Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res. 2004; 64; 5535-5538.
74. Okita R, Saeki T, Takashima S, Yamaguchi Y, Toge T. CD4+ CD25+ regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer. Oncol. Rep. 2005; 14; 1269-1273.
75. Nagorsen D, Voigt S, Berg E, Stein H, Thiel E, Loddenkemper C. Tumor-infiltrating macrophages and dendritic cells in human colorectal cancer: relation to local regulatory T cells, systemic T-cell response against tumor-associated antigens and survival. J. Transl. Med. 2007; 5; 62-70.
76. Shindo M, Yoshida Y. Regulatory T cells and skin tumors. Recent Pat. Inflamm. Allergy Drug. Discov. 2010; 4; 249-254.
77. Alvaro T, Lejeune M, Salvado MT et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin. Cancer Res. 2005; 11; 1467-1473.
78. Tzankov A, Meier C, Hirschmann P, Went P, Pileri SA, Dirnhofer S. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica 2008; 93; 193-200.
79. Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM. CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T cells. Blood 2007; 110; 2537-2544.
80. Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM. Attenuation of CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin's lymphoma. Cancer Res. 2006; 66; 10145-10152.
81. Mittal S, Marshall NA, Duncan L, Culligan DJ, Barker RN, Vickers MA. Local and systemic induction of CD4+CD25+ regulatory T-cell population by non-Hodgkin lymphoma. Blood 2008; 111; 5359-5370.
82. Betz AG, Neuberger MS, Milstein C. Discriminating intrinsic and antigen-selected mutational hotspots in immunoglobulin V genes. Immunol. Today 1993; 14; 405-411.
83. Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM. Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell non-Hodgkin's lymphoma. Cancer Res. 2009; 69; 5522-5530.
84. Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004; 10; 942-949.
85. Farinha P, Al-Tourah A, Gill K, Klasa R, Connors JM, Gascoyne RD. The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation. Blood 2010; 115; 289-295.
86. Fiore F, Von Bergwelt-Baildon MS, Drebber U et al. Dendritic cells are significantly reduced in non-Hodgkin's lymphoma and express less CCR7 and CD62L. Leuk. Lymphoma 2006; 47; 613-622.
87. Kurtova AV, Tamayo AT, Ford RJ, Burger JA. Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting. Blood 2009; 113; 4604-4613.
88. Jahnke K, Coupland SE, Na IK et al. Expression of the chemokine receptors CXCR4, CXCR5, and CCR7 in primary central nervous system lymphoma. Blood 2005; 106; 384-385.
89. Husson H, Freedman AS, Cardoso AA et al. CXCL13 (BCA-1) is produced by follicular lymphoma cells: role in the accumulation of malignant B cells. Br. J. Haematol. 2002; 119; 492-495.
90. Smith JR, Braziel RM, Paoletti S, Lipp M, Uguccioni M, Rosenbaum JT. Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma. Blood 2003; 101; 815-821.